SEC Form 4 · accession 0001179110-18-002191
Theravance Biopharma, Inc. · TBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alsup Laurie Smaldone
Director
Period of report
Feb 13, 2018
Accepted (ET)
Feb 15, 2018 · 5:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001583107
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | Feb 13, 2018 | A | 1,776 | $0.00 | A | 1,776 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to Buy)F1 | $28.14 | Feb 13, 2018 | A | 12,000 | A | — | Feb 12, 2028 | Ordinary Shares | 12,000 | 12,000 | D |
| Share Option (Right to Buy)F2 | $28.14 | Feb 13, 2018 | A | 1,500 | A | — | Feb 12, 2028 | Ordinary Shares | 1,500 | 1,500 | D |
Explanation of responses
- F1The option vests monthly over 24 months of service from the date of grant.
- F2This option shall vest monthly over three months of service from the date of grant and in full on the date of the Company's 2018 annual meeting of shareholders.